GLP-1 Medications and Bone Density: Clinical Considerations

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medications like semaglutide and tirzepatide have demonstrated significant benefits for weight loss and cardiometabolic health, but recent observational data has raised questions about potential effects on bone mineral density (BMD) with prolonged use. A 2023 study published in JAMA found modest BMD decreases in some GLP-1 users over 12+ months, though causality remains unclear.

For patients considering or already using GLP-1 therapy, bone health represents one component of a comprehensive long-term risk-benefit analysis. PlexusDx emphasizes precision-guided conversations with providers by incorporating biomarker context and genetic predispositions that may influence both GLP-1 responsiveness and skeletal health trajectories.

Bone Density Changes and GLP-1 Use: What the Evidence Shows

Observational data from GLP-1 users indicates modest BMD reductions, particularly at the hip and lumbar spine, ranging from 1–3% annually in some cohorts. However, these findings emerge primarily from short-term studies (12–24 months) and lack long-term randomized controlled trial data confirming causality or clinical fracture risk.

Weight loss itself can contribute to BMD decline independent of medication, as reduced body weight decreases mechanical loading on bone. Disentangling GLP-1-specific effects from weight loss effects remains an active area of clinical investigation. Providers must consider baseline BMD, fracture risk, and individual bone health trajectories when evaluating this concern.

Bone Health Risk Factors and GLP-1 Responsiveness: A Personalized Framework

Individual bone health risks vary significantly based on age, sex, baseline BMD, family history, nutrition status, and lifestyle factors. Some patients may tolerate GLP-1 use with minimal BMD impact, while others—particularly older adults or those with osteopenia—warrant closer monitoring and preventive strategies.

Risk Factor Category	Clinical Significance for GLP-1 Users
Age 65+ and postmenopausal females	Higher baseline fracture risk; estrogen decline and GLP-1 effects may compound BMD loss
Baseline osteopenia or osteoporosis	Requires BMD monitoring before and during GLP-1 use; may need calcium, vitamin D, or bone-protective agents
Rapid weight loss (>10% body weight)	Accelerates BMD decline; slower weight loss or resistance training may mitigate skeletal impact
Low baseline protein or micronutrient intake	Inadequate protein/calcium/vitamin D impairs bone remodeling; nutritional optimization critical during GLP-1 therapy

Mechanisms Underlying GLP-1 and Bone Metabolism: Current Understanding

GLP-1 receptor signaling may influence osteoblast (bone-forming cell) activity and bone turnover through direct and indirect pathways. Weight loss-induced changes in hormones like leptin and estrogen, plus altered mechanical stress on skeleton, can reduce bone formation rates and increase resorption, particularly early in treatment.

Semaglutide and tirzepatide differ slightly in their systemic effects, but both promote rapid weight loss that statistically correlates with BMD decline. The degree of BMD impact varies among individuals, suggesting genetic and metabolic predisposition factors may modulate skeletal responses to GLP-1 therapy.

Monitoring, Prevention, and Provider Guidance: Building a Bone-Smart Plan

Patients starting or continuing GLP-1 therapy should discuss baseline BMD screening (via DEXA scan or similar) with their provider, particularly if age 65+, postmenopausal, or have risk factors. Repeat imaging every 2–3 years during long-term GLP-1 use can track any changes and inform preventive interventions such as weight loss moderation, resistance training, or supplementation.

Optimizing calcium intake (1,000–1,200 mg daily), vitamin D status (target 30–50 ng/mL), and protein consumption (1.2–1.6 g/kg body weight) supports bone turnover during weight loss. Resistance and weight-bearing exercises further strengthen bone and mitigate GLP-1-associated BMD decline. Providers may recommend bone-protective medications (e.g., bisphosphonates) for high-risk individuals with significant BMD loss during therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in GLP-1 receptor (GLP1R rs6923761), GIPR (rs1800437), and metabolic pathways (FTO rs9939609, MC4R rs17782313) that may help provide context for how your body processes these medications. While genetic variants do not predict bone density outcomes directly, they may inform discussions with your provider about metabolic rate, weight loss trajectory, and nutritional needs during GLP-1 use.

Understanding your genetic predisposition to GLP-1 responsiveness can support conversations about monitoring frequency, nutritional optimization, and exercise strategies tailored to your individual response profile. The Precision Peptide test reveals how variants in peptide regulatory pathways may influence both treatment efficacy and systemic metabolic adjustments—factors your provider can use when counseling on bone health surveillance during long-term GLP-1 use.

By integrating genetic insights with baseline bone health assessment and nutritional status, you and your provider can develop a more personalized long-term GLP-1 plan that addresses cardiometabolic benefits while mitigating skeletal risks through targeted monitoring, supplementation, and lifestyle interventions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.